tiprankstipranks
Advertisement
Advertisement

Little Green Pharma’s Cannatrek Acquisition Scheme Cleared by Court and Becomes Effective

Story Highlights
  • Little Green Pharma is a global medicinal cannabis producer with integrated operations and strong market positions across Europe and Australia.
  • The Federal Court has approved LGP’s now-effective scheme to acquire Cannatrek, with completion set for 1 June 2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Little Green Pharma’s Cannatrek Acquisition Scheme Cleared by Court and Becomes Effective

Meet Samuel – Your Personal Investing Prophet

Little Green Pharma Ltd. ( (AU:LGP) ) just unveiled an announcement.

Little Green Pharma Ltd, a leading medicinal cannabis producer and distributor with vertically integrated operations in Europe and Australia, supplies cannabis-based medicines across Australia and over a dozen export markets. The company operates major production facilities in Denmark and Australia and ranks among the top suppliers in Australia, France, Germany, and the UK, positioning it as a key player in the global medicinal cannabis industry.

The Federal Court of Australia has approved Little Green Pharma’s scheme of arrangement to acquire 100% of Cannatrek Ltd, with the scheme now legally effective following lodgement of court orders with ASIC. Cannatrek shareholders are scheduled to receive their scheme consideration on 1 June 2026, after the 25 May 2026 record date, paving the way for the creation of a newly combined entity that is expected to enhance LGP’s scale and presence in the medicinal cannabis market.

The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.

More about Little Green Pharma Ltd.

Little Green Pharma Ltd is a global medicinal cannabis company with vertically integrated operations across Europe and Australia. It produces and distributes a diverse range of cannabis-based medicines through wholesalers, pharmacies, clinics, and GPs in Australia and more than 12 export markets, generating revenue from both product sales and its Health House distribution business. The company operates three production facilities in Denmark and Australia, including one of Europe’s largest, and is among the top suppliers in Australia, France, Germany, and the UK, giving it a strong foothold in high‑growth medicinal cannabis markets and leveraged exposure for investors.

Average Trading Volume: 124,206

Technical Sentiment Signal: Sell

Current Market Cap: A$29.06M

For detailed information about LGP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1